[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"de-escalation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:de-escalation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100631306","primary-rplnd-versus-systemic-chemotherapy-in-good-prognosis-metastatic-testicular-cancer-100631306",false,"NCT07498959","Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease","TESTIGO","Inclusion Criteria:\n\n* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A\u002FB (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)\n\nExclusion Criteria:\n\n* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)\n* Previous RPLND\n* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires","MALE","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:\n\nDoes primary RPLND lower the risk of side-effects compared to receiving chemotherapy?",[27,28,29,30,31],"Testicular Cancer","Seminoma","Quality of Life","De-escalation","RPLND",[33,34,35],"testicular cancer","seminoma","primary RPLND","RECRUITING","2026-03-24",{"date":39,"type":40},"2026-03-27","ACTUAL",{"date":42,"type":40},"2026-03-19",{"date":44,"type":21},"2032-03-25",{"name":46,"class":47},"Sahlgrenska University Hospital","OTHER"]